Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Revenue
€ 3.8 million
▼ 36% vs 2024
Profit
Caution€ -1.2 million
▲ 92% vs 2024
Debts
Low€ 14.4 million
▲ 108% vs 2024
Hyloris Pharmaceuticals from Liège, company number BE0674494151, closed financial year 2025 with a result of € -1.2 million after tax. For that financial year Hyloris Pharmaceuticals recorded revenue of € 3.8 million and equity of € 87.2 million. Compared with financial year 2024, the result moved from € -14.4 million to € -1.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
What happened at Hyloris Pharmaceuticals?
What happened at Hyloris Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Biofinance Consulting BV stepped down as director. NBB
- Jacobsen Management SRL stepped down as director. NBB
- Sybefica Invest SPRL stepped down as director. NBB
- SVR Management SRL stepped down as director. NBB
- Stefan Yee stepped down as director. NBB
- IRYL Partners SAS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.2 million. Source: NBB ↗
- Biofinance Consulting BV became a director. NBB
In short
From € 7.7 million loss in 2021 to € 1.2 million loss in 2025.
Paid € 322,958 in corporate taxes since 2021.
A new publication or filing at Hyloris Pharmaceuticals? We notify you, reason included.
Follow Hyloris PharmaceuticalsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Stijn Van Rompay (27.7%), Thomas Jacobsen (12.3%), Scorpiaux BV (6.2%), Nick Reunbrouck (5.8%), Pieter Van Rompay (3.3%) and Dietmar Aichhorn (0.1%). It owns 100% of Hyloris Developments, 100% of Hyloris Therapeutics, 100% of Dermax, 100% of Hyloris SA and 20% of FHP itself.
Directors
According to the 2025 annual accounts
Director · represented by Mélanie Mestdagt
since 2025 · until 2028
Managing director · represented by Thomas Jacobsen
Also active at: Hyloris Developments, DERMAX, Hyloris
since 2024 · until 2028
Director · represented by Vincent Van Dessel
since 2025 · until 2028
Managing director, Director · represented by Stijn Van Rompay, Léon Van Rompay
Also active at: Hyloris Developments, DERMAX, Hyloris
since 2024 · until 2028
Stefan Yee
Chairman of the board
Also active at: AED DISTRIBUTION, AED Rent, MARREYT CLASSICS +21 more
since 2024 · until 2028
Director · represented by Revital Rattenbach
since 2025 · until 2028
Shareholders
Stijn Van Rompay
27.7%
Thomas Jacobsen
12.3%
6.2%
Nick Reunbrouck
5.8%
Pieter Van Rompay
3.3%
Dietmar Aichhorn
0.1%
Participations
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments same network
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX same network
€ 1.6 million revenue · 2025
Hyloris same network
€ 384,852 revenue · 2025
Hirundo Biosciences
€ 0 revenue · 2025
+18 more
Details
- Company number
- 0674.494.151
- VAT number
- BE 0674.494.151
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 1, 4000 Liège
- Names & denominations
- Hyloris Pharmaceuticals · Hyloris
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 April 2017
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Activiteiten van holdings
Overige zakelijke dienstverlening, neg
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van hoofdkantoren
Vervaardiging van farmaceutische grondstoffen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
+1